HuGE Literature Finder
Records
1
-
30
| Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients. Neoplasma 2021 Mar . Hu Lili, Mao Xintong, Gao Chao, Xu Yinhai, Li Chenglin, Wang Tao, Lv Dongm |
| Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. The pharmacogenomics journal 2021 Jan . Vivaldi Caterina, Crucitta Stefania, Catanese Silvia, Cucchiara Federico, Arrigoni Elena, Pecora Irene, Rofi Eleonora, Fornaro Lorenzo, Salani Francesca, Massa Valentina, Vasile Enrico, Morganti Riccardo, Danesi Romano, Del Re Marz |
| Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
| Analysis of clinicopathological and molecular features of crawling-type gastric adenocarcinoma. Diagnostic pathology 2020 Sep 15 (1): 111. Fujita Yasuko, Uesugi Noriyuki, Sugimoto Ryo, Eizuka Makoto, Toya Yosuke, Akasaka Risaburo, Matsumoto Takayuki, Sugai Tamot |
| Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer. The International journal of biological markers 2019 Oct 1724600819882940. Li Jing, Xu Dan, Huang Jian, Wang Yan-Na, Ma Xiao-Ping, Lin Zhi-Yi, Gong Pi |
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Pharmacogenetics and genomics 2019 Mar . Innocenti Federico, Jiang Chen, Sibley Alexander B, Denning Stefanie, Etheridge Amy S, Watson Dorothy, Niedzwiecki Donna, Hatch Ace J, Hurwitz Herbert I, Nixon Andrew B, Furukawa Yoichi, Kubo Michiaki, Crona Daniel J, Kindler Hedy L, McLeod Howard L, Ratain Mark J, Owzar Kour |
| CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2019 Mar . Liu Duo, Li Xiang, Li Xuehua, Zhang Mingyan, Zhang Juan, Hou Dan, Tong Zhiqiang, Dong M |
| Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. British journal of clinical pharmacology 2018 Dec . Cohen R, Preta L H, Joste V, Curis E, Huillard O, Jouinot A, Narjoz C, Thomas-Schoemann A, Bellesoeur A, Tiako Meyo M, Quilichini J, Desaulle D, Nicolis I, Cessot A, Vidal M, Goldwasser F, Alexandre J, Blanchet |
| Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. Pharmacological research 2017 Aug . Lam Siu W, van der Noort Vincent, van der Straaten Tahar, Honkoop Aafke H, Peters Godefridus J, Guchelaarc Henk-Jan, Boven Ep |
| Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological research 2017 Mar 120 133-137. Pellicer Marta, García-González Xandra, García María I, Robles Luis, Grávalos Cristina, García-Alfonso Pilar, Pachón Vanessa, Longo Federico, Martínez Virginia, Blanco Carolina, Iglesias Irene, Sanjurjo María, López-Fernández Luis |
| Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. The pharmacogenomics journal 2016 Dec . Meulendijks D, Rozeman E A, Cats A, Sikorska K, Joerger M, Deenen M J, Beijnen J H, Schellens J H |
| The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer treatment reviews 2016 Nov 50 9-22. Lam S W, Guchelaar H J, Boven |
| Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene 2015 Mar 559 (1): 31-7. Ding Xiangxiang, Chen Wenwei, Fan Haijian, Zhu B |
| Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget 2015 Mar 6 (8): 6422-30. García-González Xandra, Cortejoso Lucía, García María I, García-Alfonso Pilar, Robles Luis, Grávalos Cristina, González-Haba Eva, Marta Pellicer, Sanjurjo María, López-Fernández Luis |
| Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. Genetics and molecular research : GMR 2014 13 (2): 3310-8. Zhou M, Ding Y J, Feng Y, Zhang Q R, Xiang Y, Wan H |
| Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics 2013 Jul 14 (9): 1047-51. Serdjebi Cindy, Seitz Jean-François, Ciccolini Joseph, Duluc Muriel, Norguet Emmanuelle, Fina Frédéric, Lacarelle Bruno, Ouafik L'houcine, Dahan Laetit |
| Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. The pharmacogenomics journal 2012 Oct 12 (5): 395-403. Farrell J J, Bae K, Wong J, Guha C, Dicker A P, Elsaleh |
| Genetic polymorphisms of XPD and CDA and lung cancer risk. Oncology letters 2012 Aug 4 (2): 247-251. Zhou Min, Wan Huan-Ying, Gao Bei-Li, Ding Yong-Jie, Jun Rong-X |
| High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation. Clinica chimica acta; international journal of clinical chemistry 2012 Aug 413 (15-16): 1284-7. Xu Jialin, Zhou Yuhong, Zhang Jing, Chen Yuancheng, Zhuang Rongyuan, Liu Tianshu, Cai Weim |
| A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational new drugs 2012 Jun 30 (3): 1164-74. Oh Do-Youn, Lee Keun Wook, Lee Kyung-Hee, Sohn Chang-Hak, Park Young Suk, Zang Dae Young, Ryoo Hun-Mo, Song Hong-Suk, Kim Jin-Soo, Kang Hye-Jin, Kim Bong-Seog, Bang Yung-J |
| Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2012 May 118 (9): 2466-75. Joerger Markus, Burgers Sjaak A, Baas Paul, Smit Egbert F, Haitjema Tjeerd J, Bard Martin P L, Doodeman Valerie D, Smits Paul H M, Vincent Andrew, Huitema Alwin D R, Beijnen Jos H, Schellens Jan H |
| Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012 Mar 23 (3): 670-7. Tibaldi C, Giovannetti E, Tiseo M, Leon L G, D'Incecco A, Loosekoot N, Bartolotti M, Honeywell R, Cappuzzo F, Ardizzoni A, Peters G |
| Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenetics and genomics 2012 Feb 22 (2): 105-16. Li Liang, Schaid Daniel J, Fridley Brooke L, Kalari Krishna R, Jenkins Gregory D, Abo Ryan P, Batzler Anthony, Moon Irene, Pelleymounter Linda, Eckloff Bruce W, Wieben Eric D, Sun Zhifu, Yang Ping, Wang Liew |
| Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Dec 6 (12): 2018-26. Ludovini Vienna, Floriani Irene, Pistola Lorenza, Minotti Vincenzo, Meacci Marialuisa, Chiari Rita, Garavaglia Daniela, Tofanetti Francesca Romana, Flacco Antonella, Siggillino Annamaria, Baldelli Elisa, Tonato Maurizio, Crinò Luc |
| Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer chemotherapy and pharmacology 2011 May . Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH |
| Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy. European journal of cancer (Oxford, England : 1990) 2011 Apr 47 (6): 839-47. Rodriguez J, Boni V, Hernández A, Bitarte N, Zarate R, Ponz-Sarvisé M, Chopitea A, Bandres E, Garcia-Foncillas |
| [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2011 Feb 131 (2): 239-46. Saito Yoshi |
| Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010 Nov 116 (22): 5325-35. Tanaka Motofumi, Javle Milind, Dong Xiaoqun, Eng Cathy, Abbruzzese James L, Li Dongh |
| Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis. Hepato-gastroenterology 0 59 (117): 1609-13. Kasuya Kazuhiko, Tsuchida Akihiko, Nagakawa Yuichi, Suzuki Yoshiaki, Suzuki Minako, Aoki Tatsuya, Abe Yuta, Shimazu Motohide, Itoi Takao, Sofuni Atsus |
| The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis. The International journal of biological markers 0 29 (3): e224-32. Li Hui, Wang Xiangling, Wang Xiuw |
- Page last reviewed:Jul 25, 2022
- Page last updated:Dec 05, 2022
- Content source: